Drug Approval | June 13, 2026
UK approves Wegovy pill in major shift in obesity treatment options
Approval is based on results from the phase 3 OASIS 4 clinical trial
Approval is based on results from the phase 3 OASIS 4 clinical trial
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
